Deficits, expectations and paradigms in British and American drug safety assessments: Prising open the black box of regulatory science

Science Technology and Human Values

Volumn 32, Issue 4, 2007, Pages 399-431

  Abraham, John ^a   Davis, Courtney ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

International comparison; Medicines safety regulation; Pharmaceutical innovation

Indexed keywords

EID: 34548176034     PISSN: 01622439     EISSN: 15528251     Source Type: Journal    
DOI: 10.1177/0162243907301002     Document Type: Article

References (103)

1. ABPI (Association of the British Pharmaceutical Industry). 1977.Guidelines for preclinical and clinical testing of new medicinal products. Part I. Laboratory investigations. London: ABPI.
2. ABPI (Association of the British Pharmaceutical Industry). 1984a. Dr John Griffin takes over as ABPI chief. ABPI News 198: 1.
3. ABPI (Association of the British Pharmaceutical Industry). 1984 b. New ABPI director stresses importance of two-way flow between Medicines Division and industry. ABPI News 198: 3.
4. Abraham, J. 1993. Scientific standards and institutional interests: Carcinogenic risk assessment of benoxaprofen in the UK and US. Social Studies of Science 23:387-444.
5. ABPI (Association of the British Pharmaceutical Industry). 1995. Science, politics and the pharmaceutical industry: Controversy and bias in drug regulation. London: UCL Press.
6. ABPI (Association of the British Pharmaceutical Industry). 2002. The political economy of medicines regulation in Britain. In The regulation of science and technology, edited by H. Lawton Smith, 221-63. Basingstoke: Palgrave.
7. Abraham, J., and G. Lewis. 2002. Citizenship, medical expertise and the capitalist regulatory state in Europe. Sociology 36:67-88.
8. Abraham, J., and E. Millstone. 1989. Food additive controls: Some international comparisons. Food Policy 14:43-57.
9. Abraham, J., and T. Reed. 2001. Trading risks for markets: The international harmonisation of pharmaceuticals regulation. Health, Risk & Society 3:113-28.
10. Abraham, J., and T. Reed. 2002. Progress, innovation and regulatory science. Social Studies of Science 32: 337-70.
11. Abraham, J., and J. Sheppard. 1997. Democracy, technocracy and the secret state of medicines control. Science, Technology, & Human Values 22:139-67.
12. Abraham, J., and J. Sheppard. 1999. The therapeutic nightmare: The battle over the world's most controversial sleeping pill. London: Earthscan.
13. Andersson, F. 1992. The drug lag issue: The debate seen from an international perspective. International Journal of Health Services 22:53-72.
14. Angell, M. 2004. The truth about the drug companies. New York: Random House.
15. Anon. 1978a. Present and future non-steroidal anti-inflammatories in the US. Scrip 268:24-25.
16. Anon. 1978b. Reckitt & Colman launches new anti-inflammatory in UK. Scrip 323:9.
17. Anon. 1978c. Carlo Erba's anti-inflammatory does well in trial. Scrip 275:23.
18. Anon. 1980. World anti-arthritic market should reach $2,400 million by 1984. Scrip 500:8.
19. Anon. 1981. Choosing a non-steroidal anti-inflammatory drug. Drug and Therapeutics Bulletin 19:53-56.
20. Anon. 1982. Farmitalia (UK) launches Flosint. Scrip 735: 7.
21. Anon. 1983a. Flosint's UK PL suspended. Scrip 856:1-3.
22. Anon. 1983b. Disease-modifying claim for Flenac. Scrip 847:15.
23. Anon. 1983c. Oxicam hearing in FRG. Scrip 836:1-5.
24. Anon. 1984a. Flenac's ADR incidence. Scrip 914:18.
25. Anon. 1984b. Nabumetone's potential outlined. Scrip 916:11-14.
26. Anon. 1984c. Scrip's review of 1984. Scrip 959:3-4.
27. Anon. 1984d. Lead-up to Flosint's PL suspension. Scrip 859:6-7.
28. Anon. 1984e. CSM recommends against Flosint return. Scrip 878:3.
29. Anon. 1986. CSM on NSAI ADRs. Part 2. Scrip 1102:25-27.
30. Anon. 1989. US vs UK new chemical entities (NCEs) between 1970-1988. Scrip 1472: 30-32.
31. Bailey, R. 1988. Dear Lilly Associate. Letter from managing director of Lilly Industries UK, March 3.
32. Barker, E.F. 1982. Clinical review of NDA 18-617 (indoprofen), July 22. New Drug Application for indoprofen (END 0160). Washington, DC: Food and Drug Administration.
33. Barker, E.F. 1984. Endyne, internal memorandum, May 25. New Drug Application for indoprofen (END 0154). Washington, DC: Food and Drug Administration.
34. Bbc. 1983. The Opren Scandal. Panorama January 10.
35. Bluhm, G.B. 1982. Radiologic assessment of benoxaprofen therapy in rheumatoid arthritis. European Journal of Rheumatology and Inflammation 5:186-97.
36. Bodewitz, H.J.H.W., H. Buurma, and G.H. de Vries. 1987. Regulatory science and the social management of trust in medicine. In The social construction of technological systems, edited by W. E. Bijker, T. Hughes, and T. Pinch, 243-59. Cambridge, MA: MIT Press.
37. Brickman, R., S. Jasanoff, and T. Ilgen. 1985. Controlling chemicals: The politics of regulation in Europe and the United States. Ithaca, NY: Cornell University Press.
38. Brown, N., B. Rappert, and A. Webster, eds. 2000. Contested futures: A sociology of prospective techno-science. Aldershot: Ashgate.
39. Brown, N., and A. Webster. 2004. New medical technologies and society: Reordering life. Cambridge: Polity Press.
40. Cbs. 1983. Oraflex. Sixty Minutes, April 17.
41. Christoforou, T. 2003. The precautionary principle and democratizing expertise: A European legal perspective. Science and Public Policy 30:205-211.
42. Coulter, A.W. 1981. Pharmacology and toxicology review of NDA 18-619 (fenclofenac), September 15. New Drug Application for Fenclofenac (FLE 0341). Washington, DC: Food and Drug Administration.
43. Coulter, A.W. 1984. Pharmacology and toxicology review of NDA 18-619 (fenclofenac), June 29. New Drug Application for Fenclofenac (FLE 0519). Washington, DC: Food and Drug Administration.
44. Csm. 1986. CSM Update: Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions. Part 2. British Medical Journal 292: 1190-1.
45. Daemmrich, A. 2002. A tale of two experts: Thalidomide and political engagement in the United States and West Germany. Social History of Medicine 15:137-58.
46. Daemmrich, A. 2004. Pharmacopolitics: Drug regulation in the United States and Germany. Chapel Hill: University of North Carolina Press.
47. Daemmrich, A., and G. Krücken. 2000. Risk versus risk: Decision-making dilemmas in the US and Germany. Science as Culture 9:505-34.
48. Delamothe, T. 1989. Drugs watchdogs and the drug industry. British Medical Journal 299:476.
49. Department of Health and Social Security. 1979. MAIL 24, notes for guidance on carcinogenicity testing on medicinal products. London: DHSS.
50. Eli Lilly. 1982. Background analysis in promotional materials for company sales representatives.
51. Epstein, S. 1996. Impure science: AIDS, activism, and the politics of knowledge. Berkeley: University of California Press.
52. Farmitalia. 1982. New Flosint (indoprofen): Towards mobility without pain (advertisement).
53. Farmitalia. 1982-84.Flosint data sheets.
54. Finkel 1981. Memorandum re: NDA 18-619 (fenclofenac). Internal memorandum 26 October (FLE 0552). Washington, DC: Food and Drug Administration.
55. FDA (Food and Drug Administration). 1983. Memorandum of meeting re: NDA 18-617 Endyne (indoprofen), Adria Laboratories, December 20 (END 0134). Washington, DC: Food and Drug Administration.
56. FDA (Food and Drug Administration). FDA Modernisation Act. Section 506(b)(3) of the Food, Drug and Cosmetic Act, amended by section 112 of FDAMA.
57. FDA (Food and Drug Administration). 2004. CDER NDAS approved in calendar years 1990-2004 by therapeutic potential and chemical type. Available from http://www.fda.gov/cder/rdmt/pstable.htm, accessed 10 January 2005.
58. Freeman, C. 1982. The economics of industrial innovation. London: Pinter.
59. Friedberg, M. 1984. Statistical review and evaluation, April 10. New Drug Application for Fenclofenac (FLE 0264). Washington, DC: Food and Drug Administration.
60. Gillespie, B., P. Eva, and R. Johnston. 1979. Carcinogenic risk assessment in the United States and Great Britain: The case of Aldrin/ Dieldrin. Social Studies of Science 9:265-301.
61. Groenewegen, P. 2002. Accommodating science to external demands: The emergence of Dutch toxicology. Science, Technology, & Human Values 27: 479-98.
62. Harter, J. 1981. Supervisor's review sign off form, October 26. New Drug Application for Fenclofenac (FLE 0026). Washington, DC: Food and Drug Administration.
63. Hilts, P.J. 2003. Protecting America's health: The FDA, business and one hundred years of regulation. New York: Alfred A. Knopf.
64. Hmso. 1968. Medicines Act 1968. London: Her Majesty's Stationery Office.
65. House of Commons. 1983. Opren parliamentary debate. Hansard (27 January): 573-85.
66. House of Commons Health Committee. 2005. The influence of the pharmaceutical industry Report, Volume 1.
67. Interagency Regulatory Liaison Group. 1979. Scientific basis for identification of potential carcinogens and estimation of risks. Journal of the National Cancer Institute 63:241-68.
68. Irwin, A., A. Dale, and D. Smith. 1996. Science and hell's kitchen: The local understanding of hazard issues. In Misunderstanding science? The public reconstruction of science and technology, edited by A. Irwin and B. Wynne, 47-64. Cambridge: Cambridge University Press.
69. Jasanoff, S. 1990. The fifth branch: Science advisers as policymakers. Cambridge, MA: Harvard University Press.
70. Jasanoff, S. 2005. Designs on nature: Science and democracy in Europe and the United States. Princeton, NJ: Princeton University Press.
71. Kelman, S. 1981. Regulating America, regulating Sweden: A comparative study of occupational safety and health policy. Cambridge, MA: MIT Press.
72. Kleinman, D.L. 1998. Untangling context: Understanding a university laboratory in the commercial world. Science, Technology, & Human Values 23:285-314.
73. Kuhn, T.S. 1962. The structure of scientific revolutions. Chicago: University of Chicago Press.
74. Marks, H.M. 1995. Revisiting the origins of "compulsory drug prescriptions". American Journal of Public Health 85:109-115.
75. Marks, L. 1999. "Not just a statistic": The history of USA and UK policy over thrombotic disease and the oral contraceptive pill, 1960s-1970s. Social Science & Medicine 49:1139-55.
76. Mills, J.A. 1974. Non-steroidal anti-inflammatory drugs. New England Journal of Medicine 288:781.
77. Murphy, P. 2001. Affiliation bias and expert disagreement in framing the nicotine addiction debate. Science, Technology, & Human Values 26:278-99.
78. Nuki, G. 1983. Non-steroidal analgesic and anti-inflammatory agents. British Medical Journal 287:39-43.
79. O'Brien, W.M. 1986. Radiological evaluation of erosions: A quantitative method for assessing long-term remittive therapy in rheumatoid arthritis. British Journal of Clinical Pharmacology 22:173S-182S.
80. Page, J.A. 1979. Re: IND 11-385 Indoprofen. Letter to Ronald Kartzinel, FDA, 20 June from James Page, Vice President, Medical Affairs, Adria Laboratories (END 0109).
81. Palmer, J.F. 1985. Letter from the Acting Director, Division of Oncology and Radiopharmaceutical Drug Products, FDA to RT French Company (subsidiary of Reckitt & Colman), February 21 (FLE 0775).
82. Perhac, R.M. 1998. Comparative risk assessment: Where does the public fit in? Science, Technology, & Human Values 23:221-41.
83. Pickstone, J.V. 1992. Series editor's introduction. In Medical innovations in historical perspective, edited by J.V. Pickstone, ix-x. Basingstoke: Macmillan.
84. Pieters, T. 2004. Hailing a miracle drug: The interferon. In Cultural approaches to the history of medicine, edited by W. de Blecourt and C. Usborne. Basingstoke: Palgrave Macmillan.
85. Pirmohamed, M., A.M. Breckenridge, N.R. Kitteringham, and B.K. Park. 1998. Adverse drug reactions. British Medical Journal 316:1295-8.
86. PMA (Pharmaceutical Manufacturers' Association). 1977. Guidelines for the assessment of drug and medicinal devise safety in animals. Washington, DC: PMA.
87. Reckitt & Colman. 1979 -81. Fenclofenc data sheets.
88. Reckitt & Colman. 1982-84. Fenclofenc data sheets.
89. Reckitt & Colman. 1984. Fenclofenc data sheet.
90. Richman, D.J. 1984. Memorandum, internal memorandum, 23 April. New Drug Application for indoprofen (END 0143). Washington, DC: Food and Drug Administration.
91. Temin, P. 1980. Taking your medicine: Drug regulation in the US. Cambridge, MA: Harvard University Press.
92. Temple, R. 1983. FDA non-appprovable letter to Norwich-Eaton Pharmacueticals, January 31 (FLE 0751). Washington, DC: Food and Drug Administration.
93. Topol, E.J. 2004. Failing the public health: Rofecoxib, Merck and the FDA. New England Journal of Medicine 351:1707-1709.
94. US Congress. 1982. The regulation of new drugs by the Food and Drug Administration: The new drug review process. Hearing before a Subcommittee of the Committee on Government Operations House of Representatives, August 3 and 4. Washington, DC: US Government Printing Office.
95. US Congress. 1983. FDA's regulation of Zomax. Hearing of the Intergovernmental Relations and Human Resources Subcommittee of the House of Representatives, April 26 and 27. Washington, DC: US Government Printing Office.
96. Van Zwanenberg, P., and E. Millstone. 2000. Beyond skeptical relativism: Evaluating the social constructions of expert risk assessments. Science, Technology, & Human Values 25:259-82.
97. Vane, J.R. 1971. Inhibition of prostaglandin synthesis as a mechanism for aspirin-like drugs. Nature New Biology 231:232-5.
98. Von Rechenberg, H.K. 1962. Phenylbutazone. London: Edward Arnold.
99. Walker, S.R., and C.E. Lumley. 1987. Reporting and under-reporting. In Adverse drug reactions, edited by R. D. Mann, 124-25. Lancashire: Parthenon.
100. Wardell, W. 1973. Introduction of new therapeutic drugs in the US and Great Britain: An international comparison. Clinical Pharmacology and Therapeutics 14:773-90.
101. WHO (World Health Organization). 1969. Principles for testing and evaluation of drugs for carcinogenicity. Technical Report Series No. 426. Geneva: WHO.
102. Wiktorowicz, M.E. 2003. Emergent patterns in the regulation of pharmaceuticals: Institutions and interests in the US, Canada, Britain, and France. Journal of Health, Politics, Policy and Law 28:615-58.
103. Woods, R.T., and P.G. Britton. 1985. Clinical psychology with the elderly. Kent: Croom Helm.